GelSana Therapeutics, Inc.

GelSana Therapeutics develops proprietary zwitterionic wound dressing technology designed to modulate overactive inflammation and support the body's natural wound healing process. The company's flagship product, CleraFlex™, is a stretchable zwitterionic wound dressing indicated for chronic wounds, surgical wounds, and burn injuries. CleraFlex features alternating positive and negative charges that create a protective barrier, calm inflammation, support healthy blood flow, balance moisture levels, and inhibit bacterial adhesion. GelSana targets high-burden chronic wound categories including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers (PUs), surgical site infections, and acute burns. The company positions its technology as a primary wound dressing capable of replacing most conventional dressing options. GelSana's zwitterionic platform is backed by clinical and scientific validation, addressing wound care applications representing approximately $44 billion in annual U.S. healthcare costs across targeted indications.